Prolongation of levodopa responses by glycineB antagonists in Parkinsonian primates

Annals of Neurology

Volumn 56, Issue 5, 2004, Pages 723-727

  Papa, Stella M ^a   Auberson, Yves P ^b   Greenamyre, J Timothy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; GLYCINE RECEPTOR; GLYCINE RECEPTOR ANTAGONIST; LEVODOPA; N (1 PHOSPHONOETHYL) 5 AMINOMETHYLQUINOXALINE 2,3 DIONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PAMQX; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; BALANCE DISORDER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG POTENTIATION; DRUG RESPONSE; MACACA; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PILOT STUDY; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DISABILITY EVALUATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GLYCINE AGENTS; LEVODOPA; MACACA MULATTA; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PILOT PROJECTS; PSYCHOMOTOR PERFORMANCE; RECEPTORS, GLYCINE;

EID: 9144274541     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20279     Document Type: Article

References (18)

1. Carlsson M, Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 1989;75:221-226.
2. Klockgether T, Turski L. NMDA antagonists potentiate anti-parkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 1990;28:539-546.
3. Greenamyre JT, Eller RV, Zhang Z, et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease [comment]. Ann Neurol 1994;35:655-661.
4. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys [see comments]. Ann Neurol 1996;39:574-578.
5. Blanchet PJ, Konitsiotis S, Whittemore ER, et al. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyltetrahydropyridine monkeys. J Pharmacol Exp Ther 1999;290: 1034-1040.
6. Steece-Collier K, Chambers LK, Jaw-Tsai SS, et al. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol 2000; 163:239-243.
7. Nash JE, Fox SH, Henry B, et al. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 2000;165:136-142.
8. Danysz W, Parsons CG. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998;50:597-664.
9. Stone TW. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci 2000;21:149-154.
10. Auberson YP, Acklin P, Bischoff S, et al. N-phosphonoalkyl-5- aminomethylquinoxaline-2,3-diones: in vivo active AMPA and NMDA(glycine) antagonists. Bioorg Med Chem Lett 1999;9: 249-254.
11. Ametamey SM, Kokic M, Carrey-Remy N, et al. Synthesis, radiolabelling and biological characterization of (D)-7-iodo-N-(1-phosphonoethyl)-5- aminomethylquinoxaline-2,3-dione, a glycine-binding site antagonist of NMDA receptors. Bioorg Med Chem Lett 2000;10:75-78.
12. Smith RD, Zhang Z, Kurlan R, et al. Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience 1993;52:7-16.
13. Papa SM, Boldry RC, Engber TM, et al. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 1995;701:13-18.
14. Hirai H, Kirsch J, Laube B, et al. The glycine binding site of the N-methyl-D-aspartate receptor subunit NR1: identification of novel determinants of co-agonist potentiation in the extracellular M3-M4 loop region. Proc Natl Acad Sci USA 1996; 93:6031-6036.
15. Chatterton JE, Awobuluyi M, Premkumar LS et al. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature 2002;415:793-798.
16. Carroll CB, Holloway V, Brotchie JM, Mitchell IJ. Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology (Berl) 1995;119:55-65.
17. Karcz-Kubicha M, Lorenz B, Danysz W. GlycineB antagonists and partial agonists in rodent models of Parkinson's disease-comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. Neuropharmacology 1999;38:109-119.
18. Parsons CG, Zong X, Lux HD. Whole cell and single channel analysis of the kinetics of glycine-sensitive N-methyl-D-aspartate receptor desensitization. Br J Pharmacol 1993;109: 213-221.